Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors.

European urology open science·2026
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.

Science advances·2026
Same author

Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literature.

JAMIA open·2026
Same author

Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in Italy.

Clinical drug investigation·2026
Same author

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.

NPJ breast cancer·2026

Related Experiment Video

Updated: May 21, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Metastatic bladder cancer: anything new?

Fabio Calabrò1, Cora N Sternberg

  • 1Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. fabiocalabro1@alice.it

Current Opinion in Supportive and Palliative Care
|May 31, 2012
PubMed
Summary

Chemotherapy is the primary treatment for metastatic bladder cancer, but new targeted drugs have not improved survival. Further research is needed for less toxic, more effective treatments for urothelial carcinoma.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: May 21, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Metastatic bladder cancer has a poor prognosis despite being chemosensitive.
  • Standard cisplatin-based chemotherapy regimens have not improved survival rates.
  • New drug combinations have failed to enhance outcomes for advanced bladder cancer patients.

Purpose of the Study:

  • To review the current role of chemotherapy in metastatic bladder carcinoma.
  • To evaluate the impact of novel targeted agents on treatment outcomes.
  • To discuss the challenges and future directions in managing metastatic urothelial carcinoma.

Main Methods:

  • Literature review of chemotherapy and targeted agents for metastatic bladder cancer.
  • Analysis of clinical trial data for novel therapeutic strategies.
  • Examination of molecular alterations and biomarkers in urothelial carcinoma.

Main Results:

  • Chemotherapy remains the standard treatment for metastatic bladder cancer.
  • Targeted agents (antiangiogenics, anti-EGFR, immunomodulatory) have not yet improved overall survival.
  • Understanding molecular patterns is key to identifying resistance mechanisms and biomarkers.

Conclusions:

  • No significant advances in metastatic bladder cancer treatment recently.
  • Targeted therapies are under investigation but lack major breakthroughs.
  • Development of less toxic, more effective agents and emphasis on clinical trial participation are crucial.